Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LUMO

Lumos Pharma Inc

Dec 11 • 04:00PM ET

4.34

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: VKTX ARDX ENTA AKRO BCRX CRBP CTMX FENC PDSB PHIO

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.28	Insider Own	32.91%	Shs Outstand	8.65M	Perf Week	0.46%
Market Cap	37.54M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	-0.12%	Shs Float	5.80M	Perf Month	-0.69%
Income	-34.92M	PEG	-	EPS next Q	-0.52	Inst Own	24.14%	Short Float	4.92%	Perf Quarter	16.35%
Sales	2.21M	P/S	16.99	EPS this Y	15.50%	Inst Trans	0.49%	Short Ratio	3.10	Perf Half Y	68.87%
Book/sh	0.57	P/B	7.64	EPS next Y	46.26%	ROA	-107.08%	Short Interest	0.29M	Perf Year	48.63%
Cash/sh	1.56	P/C	2.78	EPS next 5Y	15.20%	ROE	-172.83%	52W Range	1.37 - 4.58	Perf YTD	36.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.27%	ROI	-318.69%	52W High	-5.15%	Beta	0.68
Dividend TTM	-	Quick Ratio	2.66	Sales past 5Y	106.75%	Gross Margin	66.03%	52W Low	216.77%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	2.66	EPS Y/Y TTM	-6.46%	Oper. Margin	-1647.57%	RSI (14)	55.58	Volatility	0.97% 1.48%
Employees	33	Debt/Eq	1.26	Sales Y/Y TTM	26.94%	Profit Margin	-1583.49%	Recom	2.00	Target Price	4.25
Option/Short	No / No	LT Debt/Eq	1.23	EPS Q/Q	13.80%	Payout	-	Rel Volume	0.00	Prev Close	4.34
Sales Surprise	-98.35%	EPS Surprise	-26.24%	Sales Q/Q	10271.43%	Earnings	Nov 12	Avg Volume	91.94K	Price	4.34
SMA20	0.34%	SMA50	3.61%	SMA200	40.73%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-21	Upgrade	Stifel	Hold → Buy	$4 → $24
Dec-03-20	Initiated	Cantor Fitzgerald	Buy	$32
Aug-26-20	Initiated	Piper Sandler	Overweight	$26
Aug-17-20	Resumed	ROTH Capital	Buy	$51
Aug-04-20	Initiated	H.C. Wainwright	Buy	$33

Dec-12-24 08:47AM	Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma (GlobeNewswire)
Nov-21-24 09:00AM	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action (GlobeNewswire)
Oct-30-24 04:05PM	Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62 Annual ESPE Meeting 2024 (GlobeNewswire)
Oct-23-24 08:00AM	Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) (GlobeNewswire) +10.38%
Oct-09-24 03:51PM	Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence (GuruFocus.com)
04:05PM	Loading…
Sep-25-24 04:05PM	Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 (GlobeNewswire) -5.19%
Sep-05-24 09:00AM	Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024 (GlobeNewswire)
Aug-15-24 09:00AM	Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-01-24 04:05PM	Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update (GlobeNewswire)
Jul-23-24 04:05PM	Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 (GlobeNewswire)
Jun-04-24 09:00AM	Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 (GlobeNewswire)
May-20-24 04:05PM	Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 (GlobeNewswire)
May-16-24 03:02AM	Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ... (GuruFocus.com) +17.41%
May-14-24 10:53PM	LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -11.30% -12.16%
04:15PM	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results (GlobeNewswire)
02:51PM	Loading…
May-09-24 02:51PM	Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 (GlobeNewswire)
Apr-18-24 04:05PM	Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings (GlobeNewswire)
Mar-20-24 08:00AM	Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 (GlobeNewswire) +7.33%
Mar-08-24 02:06PM	Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:54PM	LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:01PM	Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update (GlobeNewswire)
Feb-26-24 09:00AM	Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 (GlobeNewswire)
Feb-05-24 04:05PM	Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-04-24 04:05PM	Lumos Pharma Promotes Pisit Duke Pitukcheewanont, MD to Chief Medical Officer (GlobeNewswire)
Nov-21-23 04:15PM	Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Nov-20-23 04:05PM	Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November (GlobeNewswire)
Nov-07-23 04:35PM	Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates (GlobeNewswire) +10.71%
04:01PM	Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints (GlobeNewswire)
Sep-26-23 09:00AM	Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting (GlobeNewswire)
Sep-14-23 08:00AM	Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting (GlobeNewswire)
04:34PM	Loading…
Sep-07-23 04:34PM	Lumos Pharma Announces Participation in Investor Conferences in September (GlobeNewswire)
Aug-22-23 09:00AM	Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape (GlobeNewswire) +7.61%
Aug-09-23 04:01PM	Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update (GlobeNewswire) -5.85% -5.77%
Jul-26-23 09:00AM	Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023 (GlobeNewswire)
Jul-12-23 08:00AM	Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit (GlobeNewswire) +6.25%
Jun-28-23 04:01PM	Lumos Pharma Announces Departure of Chief Medical Officer (GlobeNewswire) -9.46%
Jun-21-23 09:00AM	Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar (GlobeNewswire)
May-31-23 08:00AM	Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference (GlobeNewswire) -7.32%
May-25-23 08:00AM	Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st (GlobeNewswire)
May-22-23 09:00AM	Lumos Pharma to Participate in World Orphan Drug Congress USA (GlobeNewswire) +6.61%
May-08-23 08:00AM	Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
May-03-23 04:05PM	Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates (GlobeNewswire) +9.09%
Apr-27-23 09:00AM	Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
Apr-19-23 09:00AM	Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire) -5.83%
Mar-09-23 04:05PM	Lumos Pharma to Participate in Oppenheimers 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023 (GlobeNewswire) -10.86%
Mar-05-23 02:00PM	Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology (GlobeNewswire)
Mar-01-23 04:05PM	Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates (GlobeNewswire)
Feb-28-23 04:05PM	Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD (GlobeNewswire) +5.20%
Feb-15-23 04:05PM	Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023 (GlobeNewswire)
Jan-03-23 09:00AM	Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023 (GlobeNewswire) +8.03%
Dec-12-22 07:30AM	KOL Review of Lumos Pharmas Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients (GlobeNewswire) -15.75%
Nov-29-22 04:05PM	Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD (GlobeNewswire)
Nov-22-22 04:05PM	Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-14-22 06:10AM	Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -34.68%
06:00AM	Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency (GlobeNewswire)
Sep-26-22 04:05PM	Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Aug-31-22 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 07:30AM	Lumos Pharma Announces Share Repurchase Program (GlobeNewswire)
Aug-09-22 04:01PM	Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -5.26%
Jul-27-22 04:05PM	Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022 (GlobeNewswire)
Jul-24-22 08:27AM	Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news for shareholders (Simply Wall St.)
Jul-20-22 08:32PM	Our long-term outlook for the stock market remains bullish: Here are 2 stocks that Oppenheimer likes (TipRanks) +9.39%
May-16-22 04:05PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 04:01PM	Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire)
May-06-22 10:25AM	Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation (Simply Wall St.)
May-05-22 09:00AM	Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial (GlobeNewswire)
Apr-26-22 09:00AM	Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022 (GlobeNewswire) +7.50%
Apr-11-22 08:30AM	Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD (GlobeNewswire)
Mar-23-22 04:05PM	Lumos Pharma to Participate in the Cantor Rare Disease Symposium (GlobeNewswire)
Mar-10-22 04:01PM	Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials (GlobeNewswire) -6.82%
09:00AM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-22 09:00AM	Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022 (GlobeNewswire)
Feb-14-22 12:05PM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Jan-05-22 09:00AM	Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.19%
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.03%
Nov-24-21 10:00AM	Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround (Zacks)
Nov-15-21 11:14AM	We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely (Simply Wall St.)
Nov-10-21 05:06PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-08-21 10:42AM	Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know (Zacks)
Nov-03-21 04:01PM	Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates (GlobeNewswire)
Oct-21-21 04:05PM	Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 (GlobeNewswire)
Sep-02-21 08:00AM	Lumos Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-16-21 09:58AM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Aug-05-21 08:00AM	Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Aug-03-21 08:00AM	Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer (GlobeNewswire) -9.04%
Aug-02-21 08:00AM	Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President (GlobeNewswire) +10.66%
Jul-26-21 04:18PM	Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board (GlobeNewswire)
Jul-22-21 08:00AM	Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021 (GlobeNewswire)
Jul-20-21 04:01PM	Lumos Pharma Announces Clinical Updates (GlobeNewswire) -12.17%
Jun-28-21 08:00AM	Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment (GlobeNewswire)
May-19-21 09:00AM	Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 09:00AM	Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit (GlobeNewswire)
May-05-21 04:01PM	Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) -7.41% -7.05%
02:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Apr-28-21 09:00AM	Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021 (GlobeNewswire)
Apr-27-21 08:00AM	Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar (GlobeNewswire)
Apr-20-21 04:05PM	Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession (GlobeNewswire)

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKew John C.	Chief Scientific Officer	Aug 06 '24	Sale	1.89	3,407	6,426	12,653	Aug 06 05:09 PM
McKew John C.	Chief Scientific Officer	Apr 03 '24	Sale	2.77	2,214	6,144	17,153	Apr 03 05:10 PM
McKew John C.	Chief Scientific Officer	Feb 06 '24	Sale	3.03	438	1,328	18,403	Feb 07 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LUMO

Lumos Pharma Inc

Upgrade your FINVIZ experience